Yuan Lu
@yuan_lu1
Followers
199
Following
105
Media
30
Statuses
208
Assistant Professor @YaleMed CORE |@HarvardChanSPH alum, conducting research bridging population health, clinical informatics, and implementation science
new haven
Joined November 2015
Just out in JAMA, we analyzed EHR data from 39M+ U.S. adults to understand uptake and disparities in semaglutide and tirzepatide prescribing for obesity (2021–2024). Only 2.3% of eligible adults received a prescription. @YaleCardiology @AniaJastreboff @hmkyale @Chungsoo_
Between 2021 and 2024, #semaglutide and #tirzepatide prescriptions in Epic-affiliated health care systems increased slightly but remained limited, with only 3% of eligible patients receiving them. https://t.co/PEzcMfyu6B
5
11
22
Semaglutide and tirzepatide prescriptions for obesity have increased among patients with preexisting cancer, with notable variation by cancer type and absence of cancer-specific guidelines. https://t.co/upXIWf6cg2
0
25
92
📢 Our new research in @JAMAOnc shows that prescribing #GLP1RAs Semaglutide & Tirzepatide for obesity among patients with pre-existing cancer is increasing — highlighting the urgent need to understand their safety and effectiveness in this understudied group. #OncoEpidemiology
0
0
0
After two years and thousands of manuscripts, I’ve learned that the real work of an editor isn’t gatekeeping — it’s partnership. My latest @JACCJournals Editor’s Page: The Partnership 🔗 https://t.co/pii9UDzvKs
#MedTwitter #AcademicMedicine #Cardiology @YaleMed @YaleSPH
7
27
135
Team-based care. Tech-enabled follow-up. Community partnerships. Dr. @yuan_lu1 and colleagues show how to finally close the BP gap. Read “Why Can’t We Get There?” in #JACC
https://t.co/mxedjhoAXw
#Hypertension #ImplementationScience
0
2
8
Honored to contribute to two @JACCJournals Viewpoints in the Spotlight Issue on the 2025 High Blood Pressure Guidelines — 💡 “Why Can’t We Get There? Understanding Persistent Hypertension in Real-World Care” 💡 “The Noise Problem: Visit-to-Visit Blood Pressure Variability and Its
0
0
2
🆕 #JACC Focus Issue: High BP Guideline Spotlight dives into the implementation failures that have led to #hypertension going undiagnosed, untreated & inadequately controlled in the U.S. & charts a path forward. Read more: https://t.co/UmCpNuSSEu
#cvPrev @JACCJournals
1
3
6
AHA/ACC Scientific Statements: Use of Risk Assessment to Guide Decision-Making for Blood Pressure Management in the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology https://t.co/iTWmEnGC2j
3
25
103
What’s novel? · One of the first large-scale, real-world assessments linking semaglutide use to both clinical outcomes and health care spending · Highlights the gap between trial efficacy & real-world effectiveness, and between clinical gains & economic impact Implications GLP-1
0
0
0
Key findings – Clinical outcomes (13–24 months after start) · Weight ↓ 3.8% overall; ↓ 5.1% in those without diabetes · BP ↓ 1–2 mmHg · Total cholesterol ↓ ~13 mg/dL · HbA1c ↓ 0.3% in diabetes, 0.1% without Benefits were smaller than trial estimates, likely reflecting
1
0
0
Why this matters Semaglutide shows remarkable weight loss & CV benefits in trials. But… what happens in routine clinical practice, with diverse patients and real-world health system costs? Our design · Multicenter, retrospective cohort · 2018–2025 data from Sentara & Yale New
1
0
0
📢 New in JAMA Network Open: In a multicenter EHR-based cohort of >23k adults, semaglutide initiation was linked to ↓ weight, BP, cholesterol & HbA1c — but ↑ health care expenditures (excluding drug cost). Bridging trial evidence to real-world impact. 🔗
1
1
4
Importantly, our data suggest that these delays aren’t due to a lack of health care contact but rather missed opportunities within routine clinical workflows. This study is a reminder of the importance of timely recognition of elevated blood pressure and the potential role of
Our findings underscore a critical gap in hypertension care: even when patients meet objective BP thresholds for hypertension, many go undiagnosed for months or even years. This diagnostic delay matters—it’s associated with lower rates of treatment and higher long-term CV risk.
0
0
1
Very important work! Honored to write an editorial for this with @khurramn1:
An absolute risk generalizable risk calculator is challenging. Led by @somijemmacho, evaluating AHA PREVENT across 4 academic health systems, we found similar discrimination but variable calibration. A universal absolute risk threshold may not suitably guide.
0
3
7